CT HB05270

Allows terminally ill patients to access investigational drugs, biological products, or devices that have completed phase one clinical trials but lack FDA approval if they have exhausted approved treatment options and obtained physician recommendation.

Requires patients to provide written informed consent detailing available treatments, potential outcomes, and that manufacturers, insurers, and healthcare providers are not obligated to cover costs or provide subsequent care.

Permits investigational drug manufacturers to provide products for free or require patients to pay manufacturing costs without liability for resulting harm.

Protects treating physicians from disciplinary action by the Department of Public Health or Connecticut Medical Examining Board for recommending investigational treatments consistent with medical standards of care.

Prohibits state officials from preventing eligible patients from accessing investigational drugs and eliminates private lawsuits against manufacturers, physicians, or other entities involved in treatment.